BioXcel Therapeutics entered a super-priority senior secured priming debtor-in-possession credit agreement with Oaktree affiliates and Qatar Investment Authority affiliates.
BTAI (BioXcel Therapeutics): sNDA decision for Igalmi, PDUFA Nov 14. One tracker puts approval odds near 10%, so it's a long shot.
DIP facility totals up to $77.25 million, including up to $19 million of new money term loans.
Facility also includes up to $58.25 million of roll-up loans converting prepetition debt, including a $1.25 million bridge loan.
Borrowings carry a 13% interest rate; roll-up interest capitalizes; 4% exit fee payable on repayment or prepayment.
Matures Jan. 27, 2027; proceeds fund Chapter 11 working capital and case costs; lenders receive superpriority claims and priming liens.
Comments